490
Participants
Start Date
December 18, 2018
Primary Completion Date
November 18, 2022
Study Completion Date
November 18, 2022
Arfolitixorin
Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus
Leucovorin
Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion
040-01 - Allgemeines Krankenhaus der Stadt Wien, Vienna
040-05 - Wilhelminenspital, Vienna
036-02 - Chris O'Brien Lifehouse, Sydney
036-03 - Westmead Hospital, Sydney
036-09 - Southern Medical Day Care Center, Wollongong
036-10 - Border Medical Oncology Research Unit, Albury
040-04 - Landesklinikum Wiener Neustadt, Wiener Neustadt
036-01 - Western Health - Sunshine Hospital, Melbourne
036-07 - Northern Health - Epping Hospital, Melbourne
036-05 - Monash Health, Melbourne
036-04 - Peninsula Health - Frankston Hospital, Frankston
040-06 - Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz
040-03 - Uniklinikum Salzburg, Salzburg
040-02 - Klinikum Klagenfurt am Wörthersee, Klagenfurt
276-12 - Charité - Universitätsmedizin Berlin, Berlin
300-04 - 251 Airforce Hospital, Athens
300-01 - Aretaieo Hospital, Athens
250-08 - Hôpital Européen, Marseille
724-06 - Hospital Universitario Reina Sofia, Córdoba
300-02 - University General Hospital Attikon, Athens
300-03 - Metropolitan General Hospital, Athens
300-05 - Metropolitan General SA, Athens
276-10 - Universitärers Cancer Center Hamburg (UCCH), Hamburg
250-06 - Centre Georges Francois Leclerc, Dijon
250-04 - Polyclinique Francheville, Périgueux
724-04 - Hospital Unviersitario 12 de Octubre, Madrid
724-09 - Hospital Universitario HM Sanchinarro, Madrid
724-02 - Hospital Regional Universitario Carlos Haya, Málaga
840-27 - Charleston Hematology Oncology Associates, Charleston
840-32 - University of Miami, Miami
840-08 - Pinellas Hematology Oncology, St. Petersburg
276-11 - Klinikum Kassel GmbH, Kassel
276-07 - Philipps-Universität Marburg, Marburg
724-05 - Hospital Universitario Virgen del Rocío, Seville
840-29 - Ashland-Bellefonte Cancer Center, Ashland
300-06 - University General Hospital of Larissa, Larissa
840-14 - University of Michigan Cancer Center, Ann Arbor
840-04 - St. Vincent Frontier Cancer Center, Billings
840-30 - Joliet Oncology-Hematology Associates, Joliet
276-03 - Krankenhaus Nordwest GmbH, Frankfurt am Main
250-05 - Clinique Sainte Anne, Strasbourg
840-06 - Cancer Center of Kansas, Wichita
250-09 - Hopital Privé Jean Mermoz, Lyon
840-22 - University of Oklahoma Stephenson Cancer Center, Oklahoma City
250-03 - Hôpital Paris Saint Joseph, Paris
250-02 - Hôpital Saint-Antoine, Paris
840-02 - The University of Texas Health Science Center, San Antonio
840-34 - Banner MD Anderson Cancer Center, Greeley
840-13 - UCH-MHS d/b/a Memorial Health System, Colorado Springs
276-01 - Klinikum der Universität München - Campus Grosshadern, München
840-24 - Banner Gateway Medical Center, Gilbert
276-09 - Klinikum Nürnberg Nord, Nuremberg
840-15 - University of Southern California, Los Angeles
250-01 - Institute Hospitalier Franco-Britannique, Levallois-Perret
276-05 - Kliniken Nordoberpfalz AG, Weiden
840-01 - HOAG Memorial Hospital, Newport Beach
250-07 - Hôpital Henri Mondor, Créteil
840-10 - Oregon Health and Science University-Knight Cancer Institute, Portland
840-19 - University of Louisville Research Foundation Inc. (ULRF), Louisville
840-12 - Rutgers Cancer Institute of New Jersey, New Brunswick
124-03 - William Osler Health System - Brampton Civi Hospital, Brampton
124-10 - Thunder Bay Regional Health Research Institute, Thunder Bay
124-07 - Sunnybrook Research Institute, Toronto
124-04 - CISSS de l'Outaouais - Hôpital de Gatineau, Gatineau
124-11 - CISSS de Chaudière-Appalaches, Lévis
124-01 - Montreal University Health Center, Montreal
124-02 - Hôpital de la Cité-de-la-Santé, Laval
124-08 - Hôpital Maisonneuve Rosemont, Montreal
124-06 - Jewish General Hospital, Montreal
124-05 - Ottawa Hospital Research Institute, Ottawa
276-02 - Universitätsklinikum Carl Gustav Carus, Dresden
276-04 - MVZ Mitte - Onkologische Schwerpunktpraxis, Leipzig
276-13 - Universitäres Krebszentrum Leipzig (UCCL), Leipzig
276-08 - Carl von Basedow Klinikum Saalekrei GmbH, Merseburg
392-10 - Aichi Cancer Center, Aichi
392-01 - National Cancer Center Hospital East, Chiba
392-09 - National Hospital Organization Shikoku Cancer Center, Ehime
392-07 - Gifu University Hospital, Gifu
392-12 - Saitama Medical University International Medical Center, Hidaka
392-05 - University of Tsukuba Hospital, Ibaraki
392-15 - Kagawa University Hospital, Kagawa
392-08 - St.Marianna University School of Medicine Hospital, Kanagawa
392-11 - National Hospital Organization Osaka National Hospital, Osaka
392-13 - Osaka General Medical Center, Osaka
392-14 - Kansai Medical University Hospital, Osaka
392-04 - Saitama Cancer Center, Saitama
392-03 - Hokkaido University Hospital, Sapporo Hokkaido
392-02 - Shizuoka Cancer Center, Shizuoka
392-06 - National Cancer Center Hospital, Tokyo
724-03 - Instituto Oncologico Baselga - Hospital Quiron, Barcelona
724-07 - Hospital del la Santa Creu i Sant Pau, Barcelona
724-01 - Vall d'Hebron Institute of Oncology, Barcelona
752-02 - Södersjukhuset, Stockholm
752-01 - Akademiska Sjukhuset, Uppsala
Lead Sponsor
Isofol Medical AB
INDUSTRY